Trends in Serum Amylase Levels in People Living with HIV: A Comparison Between INSTI and NNRTI/PI-Based Regimens
Viruses · 2025
DOI: 10.3390/v18010045 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Viruses, 2025. Verfasst von Elena Rabinovich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Allergy and AIDS, Kaplan Medical Center, Rehovot 76100, Israel. Hauptthemen laut MEDLINE: HIV Infections, Amylases, HIV Integrase Inhibitors, Reverse Transcriptase Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antiretroviral therapy (ART) has transformed HIV into a chronic manageable condition, yet metabolic toxicities including pancreatic enzyme alterations remain concerns. While older ART regimens have been associated with hyperamylasemia, the impact of integrase strand transfer inhibitor (INSTI)-based therapies on serum amylase levels has not been specifically examined.
Purpose
This study aimed to compare longitudinal patterns of serum amylase levels between people living with HIV receiving INSTI-based versus NNRTI/PI-based ART regimens.
Methods
This retrospective observational study analyzed 99 HIV-positive patients at Kaplan Medical Centre, Israel (2002–2023). Participants received either INSTI-based (n = 49) or NNRTI/PI-based (n = 50) regimens for ≥24 months. Serum amylase, viral load, CD4 counts, and metabolic parameters were measured at baseline, one year, and two years. Repeated-measures ANOVA assessed longitudinal changes.
Results
NNRTI/PI-treated patients maintained significantly higher mean amylase levels throughout follow-up (baseline: 122.9 ± 42.1 U/L; two years: 129.6 ± 38.0 U/L) compared to INSTI-treated patients (baseline: 78.7 ± 32.3 U/L; two years: 68.4 ± 23.4 U/L; p < 0.0001 at all timepoints). A significant linear time-by-group interaction (p = 0.037) demonstrated divergent trajectories. No clinical pancreatitis was observed in either treatment group during the follow-up period, and all observed variations in serum amylase were biochemical and asymptomatic. While these findings are reassuring regarding acute pancreatic toxicity, the clinical significance of chronic subclinical enzyme elevations remains uncertain.
Conclusion
INSTI-based antiretroviral regimens suggest a favorable pancreatic and metabolic safety profile compared with NNRTI/PI-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Allergy and AIDS, Kaplan Medical Center, Rehovot 76100, Israel.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
- Department of Internal Medicine B, Kaplan Medical Center, Rehovot 76100, Israel.
- Department of Cardiology, Kaplan Medical Center, Rehovot 76100, Israel.
ORCID-Profile: Ramon Cohen, Haitham Abu Khadija, Keren Mahlab-Guri, Daniel Elbirt
Zitieren
APA
Rabinovich, E., Cohen, R., Nemet, S., Khadija, H. A., Bezalel-Rosenberg, S., Asher, I., Mahlab-Guri, K., & Elbirt, D. (2025). Trends in Serum Amylase Levels in People Living with HIV: A Comparison Between INSTI and NNRTI/PI-Based Regimens. Viruses. https://doi.org/10.3390/v18010045
Vancouver
Rabinovich E, Cohen R, Nemet S, Khadija HA, Bezalel-Rosenberg S, Asher I, et al. Trends in Serum Amylase Levels in People Living with HIV: A Comparison Between INSTI and NNRTI/PI-Based Regimens. Viruses. 2025. doi:10.3390/v18010045
BibTeX
@article{Rabinovich2025,
author = {Rabinovich, Elena and Cohen, Ramon and Nemet, Shay and Khadija, Haitham Abu and Bezalel-Rosenberg, Shira and Asher, Ilan and Mahlab-Guri, Keren and Elbirt, Daniel},
title = {Trends in Serum Amylase Levels in People Living with HIV: A Comparison Between INSTI and NNRTI/PI-Based Regimens},
journal = {Viruses},
year = {2025},
doi = {10.3390/v18010045}
}
EUVIMED